New Delhi: 22nd November 2013
Cadila Pharmaceuticals, on Thursday, launched a new lung cancer drug, Mycidac-C. The drug is priced at Rs.40,000 for a 10-course injection, much cheaper than the drugs manufactured and sold in the market by multinational companies at present. The drug, which will be available in the market in India early next month, has been developed by Cadila after 15 years of research. The new drug has been licensed and approved by the Drug Controller General of India (DCGI).
Health News Update